Oxalate decarboxylase crystals, including stabilized crystals, such as cross-linked crystals of oxalate decarboxylase, are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using oxalate decarboxylase crystals are also disclosed. Additionally disclosed are methods of producing protein crystals.

A circuit for extracorporeal blood circulation comprising a feeding line(s) adapted to take blood to be treated from a patient and a return line(s) adapted to reintroduce treated blood into the patient; at least one oxygenation device connected at inlet to the feeding line and at outlet to the return line and at least one inlet port of the blood to be treated and at least one outlet port of the treated blood, at least one inlet channel and at least one outlet channel of a working gas comprising at least one of either air or oxygen to supply oxygen to the blood to be treated and/or to remove carbon dioxide therefrom; at least one feeding device of the working gas connected to the inlet channel; and an ozone dispensing device(s) connected to the inlet channel to introduce ozone into working gas entering the oxygenation device.

A system and method for pumping fluid using a set of interconnected pump cassettes is disclosed. Each of the pump cassettes can receive a first solution in a first pumping chamber and each of the pump cassettes can receive separate second solutions in respective second pumping chambers, so that the first solution can be mixed with the separate second solutions, each said mixture capable of being placed in separate containers. The system includes a control assembly for operating each pump cassette, each pump cassette having a flexible membrane to pump fluid into and out of the pumping chambers, and each pump cassette configured for mating with a base unit that provides positive or negative pneumatic pressure to the flexible membrane.

A method of performing dialysis includes: recirculating a dialysis fluid from a patient or a dialyzer for at least two cycles, each cycle contacting the dialysis fluid first with a zirconium phosphate layer followed by at least one of a urease layer, a zirconium oxide layer, or a carbon layer; storing the recirculated dialysis fluid in a storage container; and transferring the dialysis fluid from the storage container to the patient or the dialyzer. In one example, the zirconium phosphate layer and the at least one of the urease layer, the zirconium oxide layer, or the carbon layer is provided by a sorbent cartridge.

The disclosure relates to methods for therapeutically targeting circulating tumor cells during hemodialysis, comprising: connecting a patient's bloodstream to a flow electroporator device, the device comprising: an array of polymeric channels, where the opposing sidewalls of each channel are lined with discontinuous sections of electrodes, interspersed by non-conductive polymer sections to generate sequential electric fields by constant direct current voltages; sequential electric fields with independently regulated intensity, duration, and polarity to induce lysis of circulating tumor cells and deliver chemotherapeutic agents to reduce the viability of circulating tumor cells; and polymeric tubing inlet and outlet for seamless integration into the bloodline tubing of any hemodialysis machine

A detoxification method includes the steps of inducing flow of patient blood through an extracorporeal device inlet and outlet in fluid connection to the circulatory system of a patient. Biological agents including lipopolysaccharide (LPS) contained within patient blood can be detoxified by passing patient blood over a biochemical reactor surface having attached or immobilized Saccharomyces boulardii alkaline phosphatase enzyme, with the biochemical reactor being contained within the extracorporeal device. An acyloxyacyl hydrolase enzyme may also be used on the biochemical reactor surface.

A method of performing dialysis includes: recirculating a dialysis fluid from a patient or a dialyzer for at least two cycles, each cycle contacting the dialysis fluid first with a zirconium phosphate layer followed by at least one of a urease layer, a zirconium oxide layer, or a carbon layer; storing the recirculated dialysis fluid in a storage container; and transferring the dialysis fluid from the storage container to the patient or the dialyzer. In one example, the zirconium phosphate layer and the at least one of the urease layer, the zirconium oxide layer, or the carbon layer is provided by a sorbent cartridge.

According to some embodiments, a system may treat blood containing metformin outside the body of a patient. The system may include one or more pumps configured to pump blood in a fluid flow path at a collective rate over 4 liters per minute. The system may include one or more heat exchangers operable to heat at least a portion of the blood to a temperature of at least 42 degrees. The system may include one or more convection dialysis modules configured to perform convection dialysis on at least a portion of the blood at least after the one or more heat exchangers allow the blood to cool one or more degrees.

A fluid treatment method, cycle treatment device, system and medical device are provided, wherein a cycle is formed by allowing a fluid to flow in a pipeline, and the cycle includes a treatment unit to treat the fluid to selectively change structures or concentrations of molecules or combinations thereof in the fluid, thereby avoiding loss of beneficial components; the fluid is treated by at least one cycle, and in any cycle, dynamic equilibrium of the total amount of the fluid in the cycle can be maintained through controlling the rate of adding the to-be-treated fluid into the cycle and the rate of the treated fluid leaving the cycle, so that the cycle is sustainable, and therefore the duration of the fluid treatment method is adjustable and can be determined based on a preset treatment target.

The present invention provides extracorporeal removal of targeting vectors applied in pretargeted therapy and diagnostics in animals and humans. The method and the means for extracorporeal removal of the targeting vectors is based on binding agents with inverse electron demand Diels-Alder (IEDDA) cycloaddition reactivity. The targeting vector comprises a therapeutic agent, a diagnostic agent or a theranostic agent and a chemical entity with IEDDA reactivity whereas the extracorporeal means comprises a column with a biocompatible solid support to which a chemical entity with complementary IEDDA reactivity is attached.